Asset Details
Do you wish to reserve the book?
Diphenylcyclopropenone and platelet‐rich plasma in the management of severe or recalcitrant alopecia areata
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Diphenylcyclopropenone and platelet‐rich plasma in the management of severe or recalcitrant alopecia areata
Do you wish to request the book?
Diphenylcyclopropenone and platelet‐rich plasma in the management of severe or recalcitrant alopecia areata
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Diphenylcyclopropenone and platelet‐rich plasma in the management of severe or recalcitrant alopecia areata
2023
Overview
Alopecia areata (AA) is a common disease characterized by hair loss with an autoimmune background. There are many lines of therapy, but no standard line for all cases. Consequently, treating severe forms of AA is challenging.
This study aimed to compare the efficacy and safety of the combination of diphenylcyclopropenone (DPCP) and platelet-rich plasma (PRP) with DPCP alone in treating patients with severe or refractory AA.
Our randomized clinical trial was conducted on patients with severe and recalcitrant AA. Group A included 13 patients who received only DPCP, while Group B included 11 patients who received both DPCP and PRP. After sensitization in both groups of patients, DPCP was applied to half the scalp weekly. In addition, PRP injection in all scalp was performed once a month in group B. The patients in both groups completed the study for six months.
The regrowth scale results were 53.85% and 54.5% for groups A and B, respectively. Although the response rate of group B was higher than that of group A, there is no statistically significant difference between the two groups.
From our clinical trial, it can be concluded that DPCP alone or combined with PRP is an effective and safe method for treating severe or recalcitrant AA.
Publisher
John Wiley & Sons, Inc
Subject
/ Adult
/ Alopecia
/ Anemia
/ Baldness
/ Combined Modality Therapy - adverse effects
/ Combined Modality Therapy - methods
/ Cyclopropanes - administration & dosage
/ Cyclopropanes - adverse effects
/ Cyclopropanes - therapeutic use
/ Female
/ Humans
/ Male
/ Patients
/ Plasma
/ Scalp
